SCHEMBL3497285

SCHEMBL3497285

CCCN1CCC2(CCCN(C(=O)OC(C)(C)C)C2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.45
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HRH3 Q9Y5N1 2/20 0.36
MMP2 P08253 1/20 0.36
MMP13 P45452 1/20 0.36
MMP14 P50281 1/20 0.36
ADAM17 P78536 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
BACE1 P56817 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
CTSD P07339 1/20 0.35
HPGD P15428 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
NR1H2 P55055 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3499124 0.90 USP30 (0.47) USP30MEN1KMT2AMAPTALDH1A1
SCHEMBL3498977 0.86 USP30 (0.45) USP30MEN1KMT2AMAPTALDH1A1
SCHEMBL3496450 0.85 ACACB (0.50) USP30MEN1KMT2AMAPTHRH3
SCHEMBL26092846 0.84 USP30 (0.50) USP30MEN1KMT2AMAPTALDH1A1
SCHEMBL3497947 0.84 USP30 (0.49) USP30MEN1KMT2AMAPTHRH3
SCHEMBL17082036 0.81 USP30 (0.49) USP30MEN1KMT2AMAPTHRH3
SCHEMBL5426355 0.79 USP30 (0.45) USP30ALDH1A1HDAC1HDAC8HDAC6
SCHEMBL5423537 0.79 HDAC1 (0.44) USP30MAPTALDH1A1MMP2MMP13
SCHEMBL26470126 0.78 USP30 (0.49) USP30HRH3HDAC1HDAC8HDAC6
SCHEMBL3497329 0.78 USP30 (0.47) USP30MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC USP30 3125/4885MEN1 4260/4885KMT2A 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.